Fracture-related infection (FRI) is an important complication related to orthopaedic trauma. Although the scientific interest with respect to the diagnosis and treatment of FRI is increasing, data on the microbiological epidemiology remains limited. Therefore, the primary aim of this study was to evaluate the microbiological epidemiology related to FRI, including the association with clinical symptoms and antimicrobial susceptibility data. The secondary aim was to analyze whether there was a relationship between the time to onset of infection and the microbiological etiology of FRI. Over a five-year period, FRI patients treated at the University Hospitals of Leuven, Belgium, were retrospectively included. The microbiological etiology and antimicrobial susceptibility data were analyzed. Patients were classified as having an early (<2 weeks after implantation), delayed (2–10 weeks) or late-onset (> 10 weeks) FRI.Purpose
Methods
The principle strategies of fracture-related infection (FRI) treatment are debridement, antimicrobial therapy, and implant retention (DAIR) or debridement, antimicrobial therapy, and implant removal/exchange. Increasing the period between fracture fixation and FRI revision surgery is believed to be associated with higher failure rates after DAIR. However, a clear time-related cut-off has never been scientifically defined. This systematic review analyzed the influence of the interval between fracture fixation and FRI revision surgery on success rates after DAIR. A systematic literature search was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, in PubMed (including MEDLINE), Embase, and Web of Science Core Collection, investigating the outcome after DAIR procedures of long bone FRIs in clinical studies published until January 2020.Aims
Methods
To analyse the effectiveness of debridement and implant retention
(DAIR) in patients with hip periprosthetic joint infection (PJI)
and the relationship to patient characteristics. The outcome was
evaluated in hips with confirmed PJI and a follow-up of not less
than two years. Patients in whom DAIR was performed were identified from our
hip arthroplasty register (between 2004 and 2013). Adherence to
criteria for DAIR was assessed according to a previously published
algorithm.Aims
Patients and Methods
To report mid-term results of PJI treated with uncemented stems. : 80 hips of PJI after THA were treated with uncemented stems from 01/1993 to 12/2012 and followed prospectively. Selection occurred for one- (n=27) or two-stage (n=53) exchange according to the Liestal algorithm. Surgical approaches were transfemoral (n=58), transgluteal (n=9) or transtrochanteric (n=13). A monoblock (Wagner SL, n=58) or modular (Revitan, n=22) revision stem was implanted. On the acetabular side 44 Müller rings, 33 Burch-Schneider cages (combined with a cemented PE-cup) and 3 press-fit cups were used. Kaplan-Meier survival was calculated for endpoints (a) persistence of infection, (b) septic/aseptic stem loosening. Radiographs were analysed for (a) subsidence, (b) distal stem integration, (c) changes in cortical thickness, (d) proximal femur restoration, (e) radiolucency around stem/cup. Mean FU was 5.2 (2–15) years. PJI was eradicated in 77 of 80 hips (96%). 3 patients (all two-stage) had a treatment failure. 2 were treated successfully with an additional two-stage exchange. In the 3rd patient we were not able to control infection and exarticulation was performed. Furthermore, one stem was revised for aseptic loosening (5 years), 1 for a broken Wagner stem (7 years) and 1 for subsidence (8 months). Stem survival after 5 years was 93% (SD ±2.5 years). 2 cups were revised for aseptic loosening and 1 for recurrent dislocations. Subsidence ≥5mm was found in 6 hips and occurred always within 3 months after surgery independent of stem type (p=0.947) and approach (p=0.691). Proximal femoral remodelling after transfemoral approach was excellent or good in 71% (32 excellent, 9 good) with no difference between one-/two-stage exchanges (p=0.288). Initial distal stem integration was 65mm medial and 66mm lateral and increased to 8mm medial (p=0.716) and 10mm lateral (p<0.001). Cortical thickness was unchanged over the entire FU period (p=0.493). Radiolucencies were seen around 26 stems, only the stem revised after 5years was rated loose. Eradication of PJI was high using our established protocol even with uncemented revision stems. Mid-term survival was independent from one-/two-stage revision and comparable to results for aseptic loosening revision.
Debridement, antibiotics and implant retention (DAIR) is an established treatment option for periprosthetic joint infection (PJI). Success rates of more than 90% cure have been reported with proper patient selection. While a meticulous debridement of the joint and an appropriate postoperative antibiotic therapy is important for treatment success, the relevance of changing mobile parts is still a matter of debate. The latter procedure is only possible with an extensive soft tissue release, potentially destabilizing the joint. Though, it is impossible with polyethylene-inlays being no longer available. The aim of this study was to evaluate whether cure of PJI with DAIR is influenced by retaining the mobile parts. Between 01/2004 and 12/2012, 36 patients with 39 episodes of THA-associated infections were treated with DAIR according to our algorithm (NEJM 2004). All patients met the IDSA criteria for DAIR with a stable implant and either a PJI diagnosed during the first postoperative month or a haematogenous PJI with infectious symptoms of less than three weeks. Patients were treated either with a complete debridement, including an exchange of all mobile parts (n=24), or with a complete debridement and retaining mobile parts (n=15). Postoperatively all patients received standardized antibiotic treatment (NEJM 2004). The patients’ mean age at the time of infection was 74 (SD 9) years. Average time between onset of symptoms and DAIR were 3.6 (0–28) days; Five patients died before the 2-year-follow-up unrelated to PJI. Mean follow-up of the remaining patients was 45.6 (24–119) months. 20 PJI were early postoperative, 15 haematogenously acquired, and four unclear. The most frequent causative microorganisms were coagulase-negative staphylococci (n=16), S. aureus (n=8), streptococci (n=5) and E. coli (n=2). Ten episodes were polymicrobial, and nine cases culture-negative. The overall success rate of all 39 episodes treated with DAIR was 95% (37/39). Two treatment failures were observed, both after haematogenous S. aureus infection and exchange of mobile parts. One of them refused further surgery and was treated with a suppressive antibiotic therapy. The other one had a one-stage exchange four months after DAIR showing a loose cup intraoperatively. Patients treated with DAIR strictly according to our treatment algorithm show a favourable result regarding overall success rate. From our data it seems debatable, whether the exchange of all mobile parts is mandatory, or should be individually evaluated in each case.
One of the most common pathogen causing musculoskeletal infections is Summary
Introduction
The treatment of peri-prosthetic joint infection
(PJI) of the ankle is not standardised. It is not clear whether
an algorithm developed for hip and knee PJI can be used in the management
of PJI of the ankle. We evaluated the outcome, at two or more years
post-operatively, in 34 patients with PJI of the ankle, identified
from a cohort of 511 patients who had undergone total ankle replacement.
Their median age was 62.1 years (53.3 to 68.2), and 20 patients
were women. Infection was exogenous in 28 (82.4%) and haematogenous
in six (17.6%); 19 (55.9%) were acute infections and 15 (44.1%)
chronic. Staphylococci were the cause of 24 infections (70.6%).
Surgery with retention of one or both components was undertaken
in 21 patients (61.8%), both components were replaced in ten (29.4%),
and arthrodesis was undertaken in three (8.8%). An infection-free
outcome with satisfactory function of the ankle was obtained in
23 patients (67.6%). The best rate of cure followed the exchange
of both components (9/10, 90%). In the 21 patients in whom one or
both components were retained, four had a relapse of the same infecting organism
and three had an infection with another organism. Hence the rate
of cure was 66.7% (14 of 21). In these 21 patients, we compared
the treatment given to an algorithm developed for the treatment
of PJI of the knee and hip. In 17 (80.9%) patients, treatment was
not according to the algorithm. Most (11 of 17) had only one criterion against
retention of one or both components. In all, ten of 11 patients
with severe soft-tissue compromise as a single criterion had a relapse-free
survival. We propose that the treatment concept for PJI of the ankle
requires adaptation of the grading of quality of the soft tissues. Cite this article
At our institution, periprosthetic hip joint infections are treated according to a previously defined treatment algorithm. Each patient is evaluated regarding risk factors such as duration of clinical signs and symptoms, stability of the implant, condition of the soft tissue, and antimicrobial susceptibility of the microorganism. Depending on these factors, either debridement with retention, one-stage exchange, or two-stage exchange with spacer (short interval, 2–4 weeks), or without spacer (long interval, 8 weeks) is performed. Very rarely, resection arthroplasty or lifetime suppression is necessary. All surgical procedures are combined with an antimicrobial therapy for 6 or 12 weeks, depending on the surgical pathway. For infection due to staphylococci, whenever possible, rifampicin is used in combination with a fluoroquinolone. From 2002–2006, 89 patients with 95 episodes (3 patients with 2 independent episodes, 3 patients with bilateral infection) of periprosthetic hip joint infection have been treated at our hospital. Five patients died within 2 years after revision, one of them with septic shock related to the periprosthetic hip joint infection. One patient is living abroad. All other patients (n=83) had consecutive follow-up visits at least until 2 years after infection treatment without recurrence. Debridement with retention has been performed in 18 episodes, one-stage exchange in 25 episodes, two-stage exchange with temporary spacer for 2–4 weeks has been performed in 26 episodes, and two-stage exchange without spacer and an interval of 8 weeks in 19 episodes. In 4 cases, immediate resection arthroplasty was performed and 3 patients received long-term suppression therapy. After debridement with retention, 3 recurrences and one event of death occurred (4/18=22.2%), 3 of them did not fulfil the criteria of the algorithm. No failure was observed after one-stage exchange (0/25). Treatment with two-stage exchange was followed by one failure in the group with spacer and short interval (1/26=3.8%), as well as one in the group without spacer and long interval (1/19=5.3%). No recurrence occurred after resection arthroplasty or suppression therapy. All 5 patients with relapse could be cured with a one- or two-stage exchange and remained without recurrence. Comparing one-stage versus two-stage exchange, one-stage exchange is known to have better functional results. It is associated with better patient acceptance, shorter hospital stay, and therefore lower economic burden. In conclusion, one-stage exchange implies no increasing risk of recurrence provided that the standards of our algorithm are considered.
Implant-associated infections do not spontaneously cure. The reason for persistence in device-associated infections is the biofilm, a specialized form of bacterial growth on surfaces. The biofilm represents a survival form of bacteria which is highly resistant against most antibiotics, and can persist over months or years as low-grade infection. Bacteria in biofilms enter a metabolically inactive state, embedded in an amorphous substance, called biofilm matrix. Together they form a complex three-dimensional structure with rudimentary communication and circulation systems. As a rule, only a combined surgical and antimicrobial management can eradicate biofilms and cure implant-associated infection. In selected patients, implant infections can be cured without implant removal with early debridement and long-term antibiotic treatment acting against biofilms. In this presentation, common pitfalls and reasons for treatment failure will be outlined and discussed.
In conclusion, using the proposed diagnostic and treatment algorithm (
In the 2-stage group (n = 50) results were lower but not significantly, with 80, 30% and 28% respectively, and 2 stems and 1 cup were revised due to aseptic loosening. One case (after one stage) developed an infection with a different pathogen and one case (after two stage exchange) had a relaps of infection.
Implants are highly susceptible to infection [
host-defense mechanisms around implants [ risk of hematogeneous infection of extravascular devices [ efficacy of prevention or antibiotic treatment [ correlation between efficacy of treatment in vivo and in vitro [ Taken together, these experiments showed that an agent acting on slow-growing and adhering microorganism is needed to eradicate device-associated infection. This requirement is only fulfilled by rifamycins in staphylococcal infection and by fluoroquinolones in infections caused by gram-negative bacilli [ In conclusion, the favorable role of rifampin has been proven in vitro, in animals and in human studies. Also the newest antistaphylococcal agents must be given in combination with rifampin in order to eliminate infection without removal of the device.